dasabuvir sodium; ombitasvir, paritaprevir, ritonavir · Abbvie · NDA 206619
Viekira Pak (Copackaged)
Earliest generic entry, as listed
18 Oct 2033
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10201542, US 9629841.
Listed patents · 15 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10201542 | product, use U-1753 | 18 Oct 2033 |
| US 9629841 | product, use U-1753 | 18 Oct 2033 |
| US 8466159 | use U-1637 | 4 Sep 2032 |
| US 8492386 | use U-1840 | 4 Sep 2032 |
| US 8680106 | use U-1637 | 4 Sep 2032 |
| US 8685984 | use U-1840 | 4 Sep 2032 |
| US 8691938 | substance, product | 13 Apr 2032 |
| US 8686026 | product | 9 Jun 2031 |
| US 8420596 | substance, product | 10 Apr 2031 |
| US 9044480 | use U-1638 | 10 Apr 2031 |
| US 9006387 | use U-1687 | 10 Jun 2030 |
| US 8642538 | substance, product, use U-1638 | 10 Sep 2029 |
| US 8188104 | substance, product, use U-1636 | 17 May 2029 |
| US 8501238 | substance, product, use U-1636 | 19 Dec 2028 |
| US 9139536 | use U-1753 | 9 Nov 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206619 · 001 · RLD · discontinued | tablet, oral | EQ 250MG BASE;12.5MG, 75MG, 50MG | 18 Oct 2033 |